Medindia LOGIN REGISTER
Medindia
CRISPR Gene Editing can Stop Progression of Triple-negative Breast Cancer
Advertisement

CRISPR Gene Editing can Stop Progression of Triple-negative Breast Cancer

Author -  Dr. Namitha Kumar, MA, PhD
Medically Reviewed by 
The Medindia Medical Review Team on August 29, 2019 at 4:37 PM
Highlights
  • Targeted, in vivo CRISPR gene therapy is used to stall the progress of triple-negative breast cancer
  • Triple-negative breast cancer (TNBC) lacking in estrogen, progesterone and HER2 receptors is the deadliest of all breast cancers with the highest mortality rates
  • This aggressive metastatic cancer has limited treatment options confined to surgery, chemotherapy and radiation
  • CRISPR genome editing was used in vivo through an injection into live mice with TNBC

CRISPR gene editing technique can now stop the progression of breast cancer, especially Triple-negative breast cancer (TNBC). CRISPR gene editing is safe in treating pediatric cancers as well, reveals a new study.

Facts About Triple-negative Breast Cancer

Triple-negative breast cancer (TNBC) lacking in estrogen, progesterone and HER2 receptors is the deadliest of all breast cancers with the highest mortality rates.

TNBC affects nearly 12 percent of women with breast cancers and involves the BRCA1 gene mutation. This aggressive metastatic cancer has limited treatment options confined to surgery, chemotherapy and radiation. There is a need to evolve new therapeutic options to tackle TNBC.

Listen to this article
0:00/0:00
Advertisement


A group of researchers led by Peng Guo, PhD and Marsha Moses, PhD, at the Vascular Biology Program at Boston Children's have successfully used targeted, in vivo CRISPR gene therapy to stall the progress of triple-negative breast cancer.

Does CRISPR Gene Editing Stop Breast Cancer Progression?

CRISPR gene editing holds out immense promise in tackling this type of aggressive metastatic cancer. However, the challenge was in the delivery of safe, non-toxic, effective non-viral vector systems for in vivo gene editing.

The study reports the synthesis and application of a tumor-targeted nanolipogel system (tNLG) for CRISPR gene editing in TNBC. This approach uses a soft nanolipogel made of non-toxic hydrogels and fatty molecules.
Advertisement

Antibodies are then attached to the gel's surface and guide the CRISPR nanoparticles to the exact tumor site. The antibodies are designed to recognize their target, ICAM-1 which is a molecule identified by Marsha Moses Lab (one of the study authors) in 2014 as a novel drug target for TNBC.

The soft and flexible gel particles successfully fused with the tumor cell membrane and entered the tumor to deliver the CRISPR load. As the CRISPR system entered the tumor cells, it knocked out the breast cancer oncogene Lipocalin 2 (Lcn2) which is primarily responsible for aggressive tumor growth and metastasis. Knocking out this oncogene Lcn2 stalled the tumor's aggressive growth and prevented metastasis. The treated mice did not show any signs of toxicity.

Is CRISPR Gene Editing Safe?

Peng Guo, the study's first author, used a soft nanoparticle enabled deeper penetration of the tumor cells with minimal side effects. They can also deliver a larger CRISPR load using this method. This method safely arrested the tumor growth by nearly 77 percent with no observed toxicity in normal tissues.

According to Moses' team, while the study focused on TNBC; they believe this safe CRISPR platform can be used to treat pediatric cancers and also deliver conventional drugs to tumor sites. This system can carry larger load of drugs and target the tumor precisely and effectively.

The study was funded by the National Institutes of Health (R01CA185530, 1DP2CA174495) and the Breast Cancer Research Foundation.

This proof-of-principle strategy was used in both mice and human tumor cells and is patent protected. The study was reported in the journal PNAS.

References:
  1. Novel CRISPR system could halt growth of triple-negative breast cancer - (http://discoveries.childrenshospital.org/triple-negative-breast-cancer-crispr/)
  2. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel - (https://www.pnas.org/content/early/2019/08/20/1904697116)


Source: Medindia
Font : A-A+

Cite this Article   close

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Health In Focus

The Eggstraordinary Superfood: Health Secrets of Eggs
Unraveling the nutritional might of eggs! Dive deep into the science-backed benefits of this superfood and its role in holistic well-being.
Favipiravir in Kids With COVID Causes Eye Color Change as a Side Effect
A recent report, highlighted a rare side-effect of COVID medication in children. Read more to find out.
Katalin Karikó and Drew Weissman Receive the Nobel Prize in Physiology or Medicine
Karikó and Weissman's mRNA breakthroughs spark a vaccine revolution, saving millions in the COVID-19 crisis.
Sugar Tax: An Innovative Health Initiative To Curb Diabetes
Is tax on sugar containing beverages an effective initiative to fight Diabetes? Read more to find out.
TB Drug Shortage in India: Can India Achieve Its Goal of Eradicating TB by 2025
Explore the dire TB drug shortage crisis in India, its consequences, and the urgent need for solutions to save lives.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

CRISPR Gene Editing can Stop Progression of Triple-negative Breast Cancer Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests